SLT Laser vs. MIGS: Which Initial Glaucoma Treatment is Best for You?

Managing glaucoma in 2026 has shifted from a “drops-first” approach to a more proactive, interventional strategy. For many Australians newly diagnosed with open-angle glaucoma or ocular hypertension, the primary choice now lies between Selective Laser Trabeculoplasty (SLT) and Minimally Invasive Glaucoma Surgery (MIGS).

If you are weighing SLT Laser vs. MIGS to determine which initial glaucoma treatment is best for you, this guide provides a comprehensive, evidence-based comparison tailored to the Australian clinical landscape. We explore the mechanisms, benefits, and long-term outcomes of both pathways to help you make an informed decision with your ophthalmologist.

See moer: Laser Eye Surgery After 40: Presbyopia Solutions and Blended Vision Options

Table of Contents

Understanding the Shift: Interventional Glaucoma in Australia

For decades, daily eye drops were the gold standard for initial treatment. However, issues with patient compliance, ocular surface disease (dry eye), and the long-term cost of medications have led Australian specialists to favor “interventional” options.

The goal of both SLT and MIGS is the same: to lower Intraocular Pressure (IOP). High IOP is the primary modifiable risk factor for optic nerve damage. By addressing the drainage system of the eye directly, these treatments can often delay or even eliminate the need for daily medication.

What is SLT Laser (Selective Laser Trabeculoplasty)?

SLT is a non-invasive, office-based laser procedure. It is frequently recommended as a first-line therapy because it is gentle, effective, and carries a very high safety profile.

How SLT Works

SLT uses a “cold” laser to target specific pigmented cells in the trabecular meshwork—the eye’s natural drainage “sieve.” Unlike older laser treatments (like ALT), SLT does not cause thermal damage or scarring. Instead, it triggers a natural biological healing response that clears the drainage channel, allowing fluid (aqueous humor) to exit the eye more efficiently.

Key Benefits of SLT

Non-Invasive: No incisions are made; the procedure is performed at a slit-lamp in a clinic.
High Success Rate: Approximately 75–80% of patients see a significant reduction in eye pressure.
Repeatable: Because it doesn’t scar the tissue, SLT can be repeated if the effect wears off after several years.
The “LiGHT” Evidence: The landmark LiGHT trial confirmed that 74% of patients treated with SLT first remained drop-free after three years.

What is MIGS (Minimally Invasive Glaucoma Surgery)?

MIGS refers to a group of surgical procedures that use microscopic-sized tools and devices to enhance the eye’s drainage. While “surgery” sounds more intense than “laser,” MIGS is significantly safer and faster than traditional glaucoma operations like trabeculectomy.

Common MIGS Devices in Australia (2026)

Australian surgeons utilize several TGA-approved devices, including:

iStent inject W: Two tiny titanium stents that bypass the blockage in the drainage canal.
Hydrus Microstent: A flexible scaffold that dilates Schlemm’s canal.
MINIject: A medical-grade silicone device that utilizes the supraciliary space for drainage (newly updated for 2026).
XEN Gel Stent: Creates a small bypass to a “bleb” under the conjunctiva.

How MIGS Works

Most MIGS procedures are performed in an operating theatre, often alongside cataract surgery. The surgeon inserts a microscopic device through a tiny incision to bypass the resistant trabecular meshwork or create a new pathway for fluid.

SLT Laser vs. MIGS: A Direct Comparison

Choosing between these two depends on your glaucoma stage, your lifestyle, and whether you also have cataracts.

Feature	SLT Laser	MIGS (e.g., iStent, Hydrus)
Invasiveness	Non-invasive (office-based)	Minimally invasive (surgical)
Anaesthesia	Numbing eye drops only	Local/Topical (often in a theatre)
Duration	~5 minutes	~10–15 minutes
Recovery	Immediate (return to work same day)	1–7 days (mild restrictions)
Ideal Candidate	Newly diagnosed / Early stage	Mild-to-moderate / Often with cataracts
Repeatable?	Yes	Generally a one-time placement
Primary Goal	Postpone or replace eye drops	Sustained IOP control / Reduce drop burden

Benefits and Outcomes: Which Should You Choose?

Why Choose SLT as Your Initial Treatment?

If you have just been diagnosed and have a healthy natural drainage angle (open-angle glaucoma), SLT is often the starting point. It is cost-effective and carries almost no risk of serious surgical complications.

Specialist Insight: Data from 2024–2026 indicates that patients who receive SLT early have a 29% slower rate of disease progression compared to those starting with eye drops.

Why Choose MIGS as Your Initial Treatment?

MIGS is frequently the “best” choice if you are already planning to have cataract surgery. Since the surgeon is already inside the eye, adding a MIGS device (like an iStent) adds very little risk but significantly increases the chances of you being “drop-free” after the operation.

MIGS may also be preferred if:

Your eye pressure is not responding to SLT.
You have a high “medication burden” (using 2+ drops daily) and want a more permanent structural solution.
You have moderate glaucoma that requires a more robust pressure drop than laser alone might provide.

Real-World Scenarios in Australia

Scenario A: The Newly Diagnosed Professional

Profile: 55-year-old, early-stage glaucoma, no cataracts.
Best Fit: SLT Laser. It is quick, can be done during a lunch break, and has a high chance of keeping them off drops for years without surgical risk.

Scenario B: The Senior with Cataracts

Profile: 72-year-old, moderate glaucoma, significant cataracts.
Best Fit: MIGS (combined with cataract surgery). This “two-birds-one-stone” approach addresses the vision loss from cataracts while simultaneously lowering eye pressure more effectively than laser alone.

Common Mistakes and How to Avoid Them

Waiting Too Long: Glaucoma is the “silent thief of sight.” Damage to the optic nerve is irreversible. Do not delay treatment because you “feel fine.”
Ignoring the Ocular Surface: Long-term use of preserved eye drops can cause severe dry eye. Both SLT and MIGS help avoid this.
Assuming Surgery is “Last Resort”: In 2026, MIGS is no longer a last resort. It is a proactive tool used early to prevent the need for more invasive “major” surgery later.

Step-by-Step: Your Treatment Journey

Comprehensive Exam: Your ophthalmologist performs gonioscopy to ensure you have “open angles.”
Target IOP Setting: A goal pressure is established based on your current damage.
Treatment Selection: You discuss SLT vs. MIGS based on your cataract status and lifestyle.
Procedure: SLT (clinic) or MIGS (theatre).
Post-Op Monitoring: Check-ups at 1 week, 4 weeks, and 3 months to ensure the pressure has reached the target.

FAQ: Frequently Asked Questions

1. Is SLT laser painful?

No. Most patients feel nothing or a slight “tapping” sensation. Numbing drops are used, and the procedure takes less than five minutes per eye.

2. Can I have MIGS if I’ve already had SLT?

Yes. Many patients start with SLT, and if the pressure begins to rise again after a few years, they transition to a MIGS procedure, particularly when it’s time for cataract surgery.

3. Does Medicare Australia cover these treatments?

Yes. Both SLT and MIGS (including standalone MIGS as of 2026) have specific Medicare Benefit Schedule (MBS) item numbers, though there may be out-of-pocket costs depending on your private health insurance and the specific device used.

4. How long do the effects of MIGS last?

MIGS devices like the iStent or Hydrus are permanent implants. Five-year data for devices like the MINIject shows sustained pressure reduction in over 80% of patients.

5. What are the risks of MIGS?

While safer than traditional surgery, risks include temporary pressure spikes, minor bleeding (hyphema), or the device becoming slightly displaced. These are usually manageable with drops.

Conclusion: Making the Best Choice for Your Vision

When comparing SLT Laser vs. MIGS, there is no single “correct” answer—only the right answer for your eyes. SLT offers a safe, non-invasive, and highly effective first step for early glaucoma. MIGS provides a powerful, long-term solution, especially for those with moderate disease or those already undergoing cataract surgery.

In the Australian healthcare system of 2026, we have more tools than ever to preserve your sight. The most important step is early intervention to keep your “drop-free” lifestyle as long as possible.

Next Step: Consult with your ophthalmologist to discuss your specific “drainage angle” and determine if you are a candidate for the 2026 updated MIGS protocols.

Internal Linking Suggestions:

Anchor: [Glaucoma eye drops side effects]
Anchor: [Cataract surgery and MIGS combination]
Anchor: [Managing dry eye in glaucoma patients]

Authoritative References:

Royal Australian and New Zealand College of Ophthalmologists (RANZCO) – Glaucoma Management Guidelines.
The Lancet – The LiGHT Trial: Selective Laser Trabeculoplasty vs Eye Drops.